Investor Relations

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the Fantom bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease.

REVA is a Delaware corporation with its corporate headquarters located in San Diego, California. REVA securities are traded on the Australian Securities Exchange ("ASX") under the symbol RVA. REVA’s international ticker symbol is RVA.AX. Its securities trade in the form of CHESS Depositary Interests ("CDIs"). The Company is also registered with the United States Securities and Exchange Commission (“SEC”), however its securities are currently not traded on NASDAQ or the New York Stock Exchange.

Oct 18, 2018 3:49 AM EDT

Copyright Nasdaq. Minimum 15 minutes delayed.
10 CDIs equivalent to one share of common stock